A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer

AHS Cancer Control Alberta30 enrolled

Overview

This study aims to provide preliminary data on the feasibility and outcomes of a 12 week exercise program on the quality of life of men with hormone refractory prostate cancer receiving docetaxel-based chemotherapy.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Prostatic Neoplasms Neoplasm Metastasis Palliative Care

Interventions

Exercise trainingBEHAVIORAL

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * diagnosis of prostate cancer * receiving docetaxel-based chemotherapy at the CCI * age 18 years or over * approval of oncologist * informed written consent Exclusion Criteria: * life expectancy less than 6 months * Karnofsky performance score less than 70 * contraindications for exercise (e.g. uncontrolled cardiac, respiratory, hypertensive or psychiatric disorder) * unable to understand, read, write and speak English * unable or unwilling to attend supervised exercise sessions 3 times weekly * unable or unwilling to complete outcome assessments

Locations (1)

Cross Cancer Institute

Edmonton, Alberta, Canada

Outcomes

Primary Outcomes

feasibility (recruitment, adherence, safety)

Secondary Outcomes

quality of life

functional abilities

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.